Next Article in Journal
Diet: A Specific Part of the Western Lifestyle Pack in the Asthma Epidemic
Next Article in Special Issue
The Migration Pattern of a Cementless Hydroxyapatite-Coated Titanium Stem under Immediate Full Weight-Bearing—A Randomized Controlled Trial Using Model-Based RSA
Previous Article in Journal
Slug Is A Surrogate Marker of Epithelial to Mesenchymal Transition (EMT) in Head and Neck Cancer
Previous Article in Special Issue
Prospective Short-Term and Return-to-Sports Results of a Novel Uncemented Short-Stem Hip Prosthesis with Metaphyseal Anchorage
Open AccessReview

Mesenchymal Stromal Cell-Based Therapy—An Alternative to Arthroplasty for the Treatment of Osteoarthritis? A State of the Art Review of Clinical Trials

1
Center for Musculoskeletal Surgery, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
2
Julius Wolff Institute, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
3
Berlin Institute of Health (BIH), 10178 Berlin, Germany
4
Berlin Institute of Health Center for Regenerative Therapies, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(7), 2062; https://doi.org/10.3390/jcm9072062
Received: 31 May 2020 / Revised: 23 June 2020 / Accepted: 24 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue State-of-the-Art Research on Hip and Knee Arthroplasty)
Osteoarthritis (OA) is the most common degenerative joint disorder worldwide and to date no regenerative treatment has been established in clinical practice. This review evaluates the current literature on the clinical translation of mesenchymal stromal cell (MSC)-based therapy in OA management with a focus on safety, outcomes and procedural specifics. PubMed, Cochrane Library and clinicaltrials.gov were searched for clinical studies using MSCs for OA treatment. 290 articles were initially identified and 42 articles of interest, including a total of 1325 patients, remained for further examination. Most of the included studies used adipose tissue-derived MSCs or bone-marrow-derived MSCs to treat patients suffering from knee OA. MSC-based therapy for knee OA appears to be safe and presumably effective in selected parameters. Yet, a direct comparison between studies was difficult due to a pronounced variance regarding methodology, assessed outcomes and evidence levels. Intensive scientific engagement is needed to identify the most effective source and dosage of MSCs for OA treatment in the future. Consent on outcome measures has to be reached and eventually patient sub-populations need to be identified that will profit most from MSC-based treatment for OA. View Full-Text
Keywords: mesenchymal stromal cell; osteoarthritis; regenerative therapy; cell-based therapy; degenerative joint disease mesenchymal stromal cell; osteoarthritis; regenerative therapy; cell-based therapy; degenerative joint disease
Show Figures

Figure 1

MDPI and ACS Style

Maleitzke, T.; Elazaly, H.; Festbaum, C.; Eder, C.; Karczewski, D.; Perka, C.; Duda, G.N.; Winkler, T. Mesenchymal Stromal Cell-Based Therapy—An Alternative to Arthroplasty for the Treatment of Osteoarthritis? A State of the Art Review of Clinical Trials. J. Clin. Med. 2020, 9, 2062.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop